Veronika Bachanova
Expertise in
30
conditions

Dr. Veronika Bachanova

Hematology
U Of M Health Clinics And Surgery Center Inc.
909 Fulton St SE, 
Minneapolis, MN 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
29 Years of Experience
Expertise in
30
conditions
U Of M Health Clinics And Surgery Center Inc.
909 Fulton St SE, 
Minneapolis, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Veronika Bachanova is a Hematologist in Minneapolis, Minnesota. Dr. Bachanova has been practicing medicine for over 29 years is highly rated in 30 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 180 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in MN
Hospital Affiliations
M Health Fairview University Of Mn
Fairview Lakes Health Services
M Health Fairview Ridges Hospital
M Health Fairview St John's Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

U of M Health Clinics and Surgery Center Inc.
909 Fulton St SE, Minneapolis, MN 55455
Other Locations
Office
516 Delaware St SE Ste 5-100, Minneapolis,, MN 55455

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
Enrollment Status: Recruiting
Publish Date: August 19, 2025
Intervention Type: Genetic
Study Phase: Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Allogeneic GDA-201 Natural Killer Cells in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Allogeneic GDA-201 Natural Killer Cells in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: March 25, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of N-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab
A Phase 1/2 Study of N-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab
Enrollment Status: Terminated
Publish Date: July 03, 2024
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: November 04, 2022
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma
Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 11, 2021
Intervention Type: Biological
Study Drugs: ACTR707, Rituximab
Study Phase: Phase 1
Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)
Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)
Enrollment Status: Active_not_recruiting
Publish Date: January 19, 2021
Intervention Type: Drug
Study Drugs: Romidepsin, Ixazomib
Study Phase: Phase 1/Phase 2
Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL)
Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL)
Enrollment Status: Completed
Publish Date: February 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
HM2014-26 DT2219 Immunotoxin for the Treatment of Relapsed or Refractory CD19 (+) and/or CD 22 (+) B-lineage Leukemia or Lymphoma
HM2014-26 DT2219 Immunotoxin for the Treatment of Relapsed or Refractory CD19 (+) and/or CD 22 (+) B-lineage Leukemia or Lymphoma
Enrollment Status: Completed
Publish Date: January 13, 2020
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

180 Total Publications

CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma: lessons learned from clinical trials and real world evidence.
CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma: lessons learned from clinical trials and real world evidence.
Journal: Leukemia & lymphoma
Published: October 10, 2025
Similar Doctors
Expertise in
14
conditions
Dr. Joleen Hubbard
Hematology | Oncology
Expertise in
14
conditions
Dr. Joleen Hubbard
Hematology | Oncology

Allina Health System

800 E 28th St, 
Minneapolis, MN 
 (2.2 miles away)
612-863-4762
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joleen Hubbard is a Hematologist and an Oncologist in Minneapolis, Minnesota. Dr. Hubbard is highly rated in 14 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Familial Pancreatic Cancer, and Hepato-Pancreato-Biliary Surgery.

Expertise in
20
conditions
Dr. Mark B. Juckett
Hematology | Hematology Oncology | Oncology
Expertise in
20
conditions
Dr. Mark B. Juckett
Hematology | Hematology Oncology | Oncology

Fairview Express Care

2450 Riverside Ave, 
Minneapolis, MN 
 (0.6 miles away)
612-672-7422
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Juckett is a Hematologist and a Hematologist Oncology provider in Minneapolis, Minnesota. Dr. Juckett is highly rated in 20 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Juckett is currently accepting new patients.

Daniel J. Weisdorf
Expertise in
12
conditions
Dr. Daniel J. Weisdorf
Hematology Oncology | Hematology
Expertise in
12
conditions
Dr. Daniel J. Weisdorf
Hematology Oncology | Hematology
516 Delaware Street Se, Strpwb Fifth Floor, Suite 5-100, Clinic 5b, 
Minneapolis, MN 
 (0.2 miles away)
612-626-2663
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Weisdorf is a Hematologist Oncology specialist and a Hematologist in Minneapolis, Minnesota. Dr. Weisdorf is highly rated in 12 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Transplant, and Bone Graft. Dr. Weisdorf is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bachanova's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 18 Advanced Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile